SUBSCRIBERS
Coronary side effects dash Amgen, UCB hopes for osteoporosis drug
Published Mon, May 22, 2017 · 09:50 PM
New York
AMGEN Inc and UCB SA no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.
The drug, romosozumab, which would be sold under the brand name Eveni…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Hilton lifts 2024 profit forecast on international travel demand
China knockoff raid jolts a global throng of fake-fashion influencers
Roche cuts pipeline after research setbacks and sales drop
Cordlife customers push for legal action
Apparel company Express seeks quick bankruptcy sale
Mattel posts narrower loss, thanks to Hot Wheels growth and lower costs